期刊文献+

抗体模拟物及多肽的研究进展及应用前景

Research progress and application prospects of antibodies mimics and peptides
下载PDF
导出
摘要 抗体是一类重要的生物药物,由于单克隆抗体技术的不断发展,在临床治疗和诊断方面起着举足轻重的作用,但也存在许多局限性,如药代动力学不足,组织可及性差、免疫原性不良和生产成本高,限制了其重复使用。目前,针对目标抗原的合成多肽及多肽的模拟物是抗体的重要替代品。本文主要通过对抗体的结构、抗原与抗体结合的特点及针对抗原特异性靶位点的抗体模拟物的最新进展加以探讨,以期为在抗体应用于临床治疗、基础研究及诊断方面所面临的问题提供理论依据及行之有效的解决措施。 Antibodies are an important class of biopharmaceuticals and they play an important role in clinical treatment and diagnosis because of the continuous development of monoclonal antibody technology.However,there are also many limitations,such as insufficient pharmacokinetics and poor tissue accessibility,dificient immunogenicity and high production costs.Currently,mimics of synthetic polypeptides and polypeptides directed against a target antigen are important substitutes for antibodies.In this paper,the structure of antibodies,the characteristics of antigen-antibody binding and the latest advances in small molecule mimics of peptide antibodies are discussed to provide theoretical basis and effective solutions for the application of antibodies in clinical treatment,basic research and diagnosis.
作者 谭小艳 李翀 顾大勇 何建安 龙军 TAN Xiao-Yan;LI Chong;GU Da-Yong;HE Jian-An;LONG Jun(Department of Laboratory Medicine,Zhujiang Hospital,Southern Medical University,Guangzhou 510280,China)
出处 《中国免疫学杂志》 CAS CSCD 北大核心 2021年第13期1663-1664,F0003,F0004,共4页 Chinese Journal of Immunology
基金 深圳市科技研发基金(JCYJ20160427151920801)资助。
关键词 多肽 抗体模拟物 结构 Polypeptide Antibody mimetic Structure
  • 相关文献

参考文献2

二级参考文献11

  • 1[7]Monfardini C, Kieber-Emmons T, Voet D, et al. Rational design of granulocyte-macrophage colony-stimulating factor antagonist peptides [J]. J Biol Chem, 1996,271(6):2966-2971. 被引量:1
  • 2[8]Levi M, Sallberg M, Ullaruden, et al. A complementarily-determining region synthetic peptide acts as a mini antibody and neutralizes human immunodeficiency virus type-1 in vitro [J]. Proc Natl Acad Sci USA, 1993,90(10):4374-4378. 被引量:1
  • 3[9]Xiong DS, Yang CZ, Shao XF, et al. Preparation and identification of anti-P-glycoprotein [J]. Chin J Hematol (中华血液学杂志), 1999,20(6):326-330. 被引量:1
  • 4[10]Yang CZ, Luan FJ, Xiong DS, et al. Multidrug resistance in leukemic cell line K562/A02 induced by doxorubicine [J]. Acta Pharmacol Sin, 1995,16(4):333-337. 被引量:1
  • 5[11]Zhang X, Piatier-Taonneau D, Auffray C, et al. Synthetic CD4 exocyclic peptides antagonize CD4 holoreceptor binding and T cell activation [J]. Nat Biotech, 1996,14(4):472-475. 被引量:1
  • 6[1]Simon SM, Schindler M. Cell biological mechanism of multidrug resistance in tumors [J]. Proc Natl Acad Sci USA, 1994,91(9):3497-3504. 被引量:1
  • 7[2]Chan HS, Haddad G, Thorner PS, et al. P-Glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma [J]. N Engl J Med, 1991,325(23):1608-1614. 被引量:1
  • 8[3]Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer, mechanisms, reversal using modulatiors of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs [J]. Eur J Pharm Sci, 2000,11(4):265-283. 被引量:1
  • 9[4]Twentyman PR. Cyclosporins as drug resistance modifiers [J]. Biomhem Pharmacol, 1992,43(1):109-117. 被引量:1
  • 10[5]Dougall WC, Peterson NC, Greene MI. Antibody-structure-based design of pharmacological agents [J]. TIBTECH, 1994,12(9):372-379. 被引量:1

共引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部